NIKKEI 225
38,097.93 -307.73 (-0.80%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.10 -0.83 (-1.01%) GOLD FUTURES
2,297.50 -5.40 (-0.23%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
47,875.49 -3,227.82 (-6.32%)
NVO Jun 2024 67.500 put
| Previous close | 0.0400 |
| Open | 0.0400 |
| Bid | 0.0000 |
| Ask | 0.0800 |
| Strike | 67.50 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0400 - 0.0400 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.02k |
Yahoo FinanceEli Lilly reports $2 billion from Mounjaro, Zepbound in Q1 2024
Eli Lilly missed on total sales in the first quarter, but its GLP-1 drugs helped boost sales by 26% over those in Q1 2023.
Investor's Business DailyIBD Stock Of The Day Eli Lilly Surges After Weight-Loss Drug Obliterates Sales Views
Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.
BloombergOzempic Maker Novo Nordisk Has Denmark’s Economy Hooked
(Bloomberg) -- There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global phenomenon. They’ve won over the rich and famous, generated billions in sales and blown open a new market for weight loss drugs, which Goldman Sachs estimates will reach $100 billion a year by 2030.Most Read from BloombergHSBC CEO Quinn Unexpectedly Steps Down After Almost 5 YearsWall Street Hit by Fed Jitters to Close Wild April: Markets WrapBinance and CZ’s Fortunes Are Set to Grow, Even in Jail
